Increased adiponectin following efruxifermin treatment is associatedwith improvements in dyslipidemia, glucose metabolism, and liver health in a 16-week, randomized, placebo-controlled trial in NASH

Correlation between changes in liver fat content and improvements in serum markers of liver injury, fibrosis, and metabolism, and in histologic parameters following treatment with efruxifermin

The role of reduction in liver fat content (MRI-PDFF) and ALT in predicting treatment response in NASH: A secondary analysis of the randomized, controlled BALANCED trial

LY2405319, an analog of fibroblast growth factor 21 ameliorates α-smooth muscle actin production through inhibition of the succinate—G-protein couple receptor 91 (GPR91) pathway in mice

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial